SCHEMBL197858

SCHEMBL197858

COC(=O)c1c(I)ccnc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
KDM4E B2RXH2 7/20 0.39
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
KDM3A Q9Y4C1 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.36
ALOX15 P16050 1/20 0.36
ALDH1A1 P00352 4/20 0.36
CYP3A4 P08684 2/20 0.36
MAPK1 P28482 2/20 0.36
ACHE P22303 1/20 0.36
TSHR P16473 3/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15455330 0.82 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL1585518 0.81 ATR (0.43) CA12CA1CA2CA7CA9
SCHEMBL3516266 0.81 CA12 (0.40) CA12CA1CA2CA7CA9
SCHEMBL1047663 0.81 CA1 (0.40) CA12CA1CA2CA7CA9
SCHEMBL21749948 0.81 ALDH1A1 (0.40) CA12CA1CA2CA7CA9
SCHEMBL30867527 0.80 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL12515865 0.80 CA12 (0.47) CA12CA1CA2CA7CA9
SCHEMBL27373972 0.79 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL14090941 0.79 CA12 (0.46) CA12CA1CA2CA7CA9
SCHEMBL18195528 0.78 CA12 (0.38) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9387202-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-12 US disclosed
US-9387202-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-12 US disclosed
US-9387202-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2016-07-12 US disclosed
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-05-28 US disclosed
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-05-28 US disclosed
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2015-05-28 US disclosed
CN-104302292-A Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS LLC 2015-01-21 CN disclosed
US-8921565-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-12-30 US disclosed
US-8921565-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-12-30 US disclosed
US-8921565-B2 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2014-12-30 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
EP-1881976-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS Amgen Inc., (US) 2008-01-30 EP disclosed
WO-2006116713-A1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148380-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 CA12 4658/4885CA1 4527/4885CA2 4458/4885
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET CA12 1787/4885CA1 2615/4885CA2 2961/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET CA12 1787/4885CA1 2615/4885CA2 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.